In many cases, we’ve simply layered new tools onto an outdated operating model. The structure beneath—the way clinical trials ...

Karen Peterson was diagnosed with stage 1 triple-negative breast cancer that quickly returned as stage 4. Joining a clinical ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

Nutcracker Therapeutics and Elegen see their mission as delivering scalable and low-cost RNA manufacturing for individualized therapies.